FDA Approves First Gene Therapy For High-Risk, Non-Muscle-Invasive Bladder Cancer

RTTNews | 1008 hari yang lalu
FDA Approves First Gene Therapy For High-Risk, Non-Muscle-Invasive Bladder Cancer

(RTTNews) - The U.S. Food and Drug Administration has approved Ferring Pharmaceuticals A/S's Adstiladrin (nadofaragene firadenovec-vncg) to treat high-risk, non-muscle-invasive bladder cancer.

Adstiladrin is a non-replicating, i.e., cannot multiply in human cells, adenoviral vector based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

It is the first gene therapy to be approved by the FDA to treat such high-risk, non-muscle-invasive bladder cancer, which is a disease in which malignant cells form a tumor in the tissues of the bladder.

According to the Centers for Disease Control and Prevention, about 57,000 men and 18,000 women are diagnosed with bladder cancer annually in the United States.

The safety and effectiveness of Adstiladrin was evaluated in a multicenter clinical study that included 157 patients with high-risk BCG-unresponsive NMIBC. Of them, 98 patients had BCG-unresponsive CIS with or without papillary tumors and could be evaluated for response.

In the trial, patients received Adstiladrin once every three months for up to 12 months, or until unacceptable toxicity to therapy or recurrent high-grade NMIBC.

Adstiladrin is administered once every three months into the bladder through a urinary catheter. Individuals who are immunosuppressed, or immune-deficient should not come into contact with Adstiladrin.

The most common adverse reactions associated with Adstiladrin included bladder discharge, fatigue, bladder spasm, urinary urgency, hematuria (presence of blood in urine), chills, fever, and painful urination.

The Adstiladrin application was granted Priority Review, Breakthrough Therapy, and Fast Track designations.

Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, "This approval provides healthcare professionals with an innovative treatment option for patients with high-risk non-muscle invasive bladder cancer that is unresponsive to BCG therapy."

For More Such Health News, visit rttnews.com

read more
Australian Market Trims Early Gains In Mid-market

Australian Market Trims Early Gains In Mid-market

The Australian stock market is trimming its early gains in mid-market trading on Monday, but adding to the gains in the previous session, following the broadly positive cues from Wall Street on Friday. The benchmark S&P/ASX 200 index is moving above the 8,800.00 level, with gains across most sectors led by mining and financial stocks.
RTTNews | 1j 52min yang lalu
Asian Markets Trade Mixed

Asian Markets Trade Mixed

Asian stock markets are trading mixed on Monday, following the positive cues from Wall Street on Friday, as the recent interest rate cut decision by the US Fed and the forecast by Fed officials of two more rate cuts this year but just one next year, continue to lift market sentiment. However, major currencies in the region weakened against the US dollar. Asian markets closed mixed on Friday.
RTTNews | 2j 12min yang lalu
Sensex, Nifty Set To Open Lower After Trump's Visa Crackdown

Sensex, Nifty Set To Open Lower After Trump's Visa Crackdown

Indian shares look set to open lower on Monday, with tech stocks likely to be in focus after U.S. President Donald Trump signed an executive order slapping an additional fee on H-1B visa holders, potentially impacting profitability and prompting companies to rethink hiring strategies.
RTTNews | 2j 48min yang lalu
Japanese Market Sharply Higher

Japanese Market Sharply Higher

The Japanese stock market is trading sharply higher on Monday, reversing the losses in the previous session, following the broadly positive cues from Wall Street on Friday, with the Nikkei 225 nearly 600 points to well above the 45,600 level, with gains across most sectors led by exporters and technology stocks.
RTTNews | 3j 5min yang lalu
Thai Stock Market Due For Support On Monday

Thai Stock Market Due For Support On Monday

The Thai stock market has moved lower in three straight sessions, shedding more than 15 points or 1.1 percent along the way. The Stock Exchange of Thailand now sits just above the 1,290-point plateau although it may stop the bleeding on Monday.
RTTNews | 3j 25min yang lalu
Indonesia Bourse May Set Fresh Record High

Indonesia Bourse May Set Fresh Record High

The Indonesia stock market bounced higher again on Friday, one day after halting the seven-day winning streak in which it had surged almost 400 points or 5 percent. Now at a fresh record closing high, the Jakarta Composite Index sits just above the 8,050-point plateau and it may see additional support on Monday.
RTTNews | 3j 55min yang lalu
Additional Support Tipped For Hong Kong Stocks

Additional Support Tipped For Hong Kong Stocks

The Hong Kong stock market has alternated between positive and negative finishes through the last four trading days since the end of the two-day winning streak in which it had jumped more than 360 points or 1.4 percent. The Hang Seng Index now sits just beneath the 26,550-point plateau and it may add to its winnings on Monday.
RTTNews | 4j 10min yang lalu